Novel |
CD48 |
CD48 molecule |
- Cell surface interactions at the vascular wall
|
|
|
Novel |
CD5 |
CD5 molecule |
|
|
|
Novel |
CD55 |
CD55 molecule (Cromer blood group) |
- Class B/2 (Secretin family receptors)
- Neutrophil degranulation
- COPI-mediated anterograde transport
- Regulation of Complement cascade
|
|
- Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
|
Novel |
CD79A |
CD79a molecule |
- CD22 mediated BCR regulation
- Potential therapeutics for SARS
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
|
Novel |
CD79B |
CD79b molecule |
- CD22 mediated BCR regulation
- Potential therapeutics for SARS
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
|
Novel |
CD8A |
CD8 subunit alpha |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
Novel |
CDC25C |
cell division cycle 25C |
- Polo-like kinase mediated events
- Activation of ATR in response to replication stress
- RHO GTPases activate PKNs
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- Cyclin A/B1/B2 associated events during G2/M transition
- Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
|
|
Novel |
CDC42 |
cell division cycle 42 |
- GPVI-mediated activation cascade
- EGFR downregulation
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- DCC mediated attractive signaling
- Inactivation of CDC42 and RAC1
- VEGFA-VEGFR2 Pathway
- Myogenesis
- Myogenesis
- RHO GTPases activate KTN1
- RHO GTPases activate IQGAPs
- RHO GTPases activate PAKs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate Formins
- RHO GTPases Activate Formins
- MAPK6/MAPK4 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- G beta:gamma signalling through CDC42
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
|
- Aminophosphonic acid-guanylate ester
- Guanosine-5'-Diphosphate
|
|
Novel |
CDC45 |
cell division cycle 45 |
- Activation of ATR in response to replication stress
- Unwinding of DNA
- Activation of the pre-replicative complex
- G1/S-Specific Transcription
|
|
|
Novel |
CDKAL1 |
CDKAL1 threonylcarbamoyladenosine tRNA methylthiotransferase |
- tRNA modification in the nucleus and cytosol
|
|
- Type II diabetes mellitus
|
Novel |
CIMIP2B |
ciliary microtubule inner protein 2B |
|
|
|
Novel |
CITED4 |
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4 |
- Activation of the TFAP2 (AP-2) family of transcription factors
|
|
|
Novel |
CSF2RB |
colony stimulating factor 2 receptor subunit beta |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
- Interleukin receptor SHC signaling
|
- Sargramostim
- NPI 32101
- Resatorvid
|
|
Novel |
CSF3R |
colony stimulating factor 3 receptor |
- Other interleukin signaling
- Transcriptional regulation of granulopoiesis
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
|
- Pegfilgrastim
- Filgrastim
- FavId
- Lenograstim
- Lipegfilgrastim
- Eflapegrastim
|
|
Novel |
CSK |
C-terminal Src kinase |
- GAB1 signalosome
- Phosphorylation of CD3 and TCR zeta chains
- Integrin signaling
- Co-inhibition by PD-1
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- RHOH GTPase cycle
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Negative regulation of FLT3
|
- Dasatinib
- Staurosporine
- TG-100801
- Fostamatinib
|
|
Novel |
CSNK2B |
casein kinase 2 beta |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
- KEAP1-NFE2L2 pathway
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- Maturation of hRSV A proteins
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
- Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
|
|
Novel |
CTDSP1 |
CTD small phosphatase 1 |
|
- Aspartate beryllium trifluoride
- Citric acid
|
|
Novel |
CTLA4 |
cytotoxic T-lymphocyte associated protein 4 |
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
|
- Abatacept
- Ipilimumab
- Tremelimumab
|
- Graves' disease
- Allograft rejection
- Type I diabetes mellitus
- Hashimoto's thyroiditis
|
Novel |
CTNND2 |
catenin delta 2 |
|
|
- Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
|
Novel |
DAPP1 |
dual adaptor of phosphotyrosine and 3-phosphoinositides 1 |
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Inositol 1,3,4,5-Tetrakisphosphate
|
|